Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023
Abstract Research on Guillain-Barré syndrome (GBS) as a neurological adverse effect of vaccines on a global scale is scarce, highlighting the need for further investigation to evaluate its long-term impact and associated risk factors comprehensively. Hence, this study aims to assess the global burde...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-10-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-74729-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849333151276466176 |
|---|---|
| author | Yi Deun Jeong Seoyoung Park Sooji Lee Woojin Jang Jaeyu Park Kyeongmin Lee Jinseok Lee Jiseung Kang Raphael Udeh Masoud Rahmati Seung Geun Yeo Lee Smith Hayeon Lee Dong Keon Yon |
| author_facet | Yi Deun Jeong Seoyoung Park Sooji Lee Woojin Jang Jaeyu Park Kyeongmin Lee Jinseok Lee Jiseung Kang Raphael Udeh Masoud Rahmati Seung Geun Yeo Lee Smith Hayeon Lee Dong Keon Yon |
| author_sort | Yi Deun Jeong |
| collection | DOAJ |
| description | Abstract Research on Guillain-Barré syndrome (GBS) as a neurological adverse effect of vaccines on a global scale is scarce, highlighting the need for further investigation to evaluate its long-term impact and associated risk factors comprehensively. Hence, this study aims to assess the global burden of vaccine-associated GBS and its associated vaccines. This study utilized data from VigiBase, the World Health Organization global database of adverse event reports of medicines and vaccines, encompassing the period from 1967 to 2023 (total reports, n = 131,255,418) to investigate vaccine-associated GBS. Reported odds ratios (ROR) and information components (IC) were analyzed to assess the association between 19 vaccines and the occurrence of vaccine-associated GBS over 170 countries. We identified 15,377 (8072 males [52.49%]) reports of vaccine-associated GBS among 22,616 reports of all drugs-cause GBS from 1978 to 2023. Cumulative reports of vaccine-associated GBS have been increasing steadily over time, with a notable surge observed since the commencement of COVID-19 vaccines administration in 2020. Most vaccines showed significant associations with GBS such as Ad5-vectored COVID-19 vaccines (ROR, 14.88; IC, 3.66), COVID-19 mRNA vaccines (ROR, 9.66; IC, 2.84), and inactivated whole-virus COVID-19 vaccines (ROR, 3,29; IC 1.69). Influenza vaccines showed the highest association (ROR, 77.91; IC 5.98). Regarding age-and sex-specific risks, the association remained similar regardless of sex, with an increased association observed with advancing age. The mean time to onset was 5.5 days. Amid the COVID-19 pandemic, the reports of GBS surged in response to widespread COVID-19 vaccination. Nonetheless, COVID-19 vaccines exhibited the lowest association compared to other vaccines. Vigilance for at least one-week post-vaccination is crucial, particularly for older adults. Further research is warranted to elucidate the underlying mechanisms linking vaccines and GBS. |
| format | Article |
| id | doaj-art-f5e124bfb6b84926ac52d5f3c7a8b430 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-f5e124bfb6b84926ac52d5f3c7a8b4302025-08-20T03:45:57ZengNature PortfolioScientific Reports2045-23222024-10-0114111210.1038/s41598-024-74729-2Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023Yi Deun Jeong0Seoyoung Park1Sooji Lee2Woojin Jang3Jaeyu Park4Kyeongmin Lee5Jinseok Lee6Jiseung Kang7Raphael Udeh8Masoud Rahmati9Seung Geun Yeo10Lee Smith11Hayeon Lee12Dong Keon Yon13Department of Medicine, Kyung Hee University College of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of MedicineDepartment of Medicine, Kyung Hee University College of MedicineDepartment of Medicine, Kyung Hee University College of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of MedicineCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of MedicineDepartment of Biomedical Engineering, Kyung Hee UniversityDivision of Sleep Medicine, Harvard Medical SchoolSchool of Life Sciences, Faculty of Science, University of Technology SydneyHealth Service Research and Quality of Life Center (CEReSS), Aix-Marseille UniversitéDepartment of Otolaryngology-Head & Neck Surgery, Kyung Hee University Medical Center, Kyung Hee University College of MedicineCentre for Health, Performance and Wellbeing, Anglia Ruskin UniversityCenter for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of MedicineDepartment of Medicine, Kyung Hee University College of MedicineAbstract Research on Guillain-Barré syndrome (GBS) as a neurological adverse effect of vaccines on a global scale is scarce, highlighting the need for further investigation to evaluate its long-term impact and associated risk factors comprehensively. Hence, this study aims to assess the global burden of vaccine-associated GBS and its associated vaccines. This study utilized data from VigiBase, the World Health Organization global database of adverse event reports of medicines and vaccines, encompassing the period from 1967 to 2023 (total reports, n = 131,255,418) to investigate vaccine-associated GBS. Reported odds ratios (ROR) and information components (IC) were analyzed to assess the association between 19 vaccines and the occurrence of vaccine-associated GBS over 170 countries. We identified 15,377 (8072 males [52.49%]) reports of vaccine-associated GBS among 22,616 reports of all drugs-cause GBS from 1978 to 2023. Cumulative reports of vaccine-associated GBS have been increasing steadily over time, with a notable surge observed since the commencement of COVID-19 vaccines administration in 2020. Most vaccines showed significant associations with GBS such as Ad5-vectored COVID-19 vaccines (ROR, 14.88; IC, 3.66), COVID-19 mRNA vaccines (ROR, 9.66; IC, 2.84), and inactivated whole-virus COVID-19 vaccines (ROR, 3,29; IC 1.69). Influenza vaccines showed the highest association (ROR, 77.91; IC 5.98). Regarding age-and sex-specific risks, the association remained similar regardless of sex, with an increased association observed with advancing age. The mean time to onset was 5.5 days. Amid the COVID-19 pandemic, the reports of GBS surged in response to widespread COVID-19 vaccination. Nonetheless, COVID-19 vaccines exhibited the lowest association compared to other vaccines. Vigilance for at least one-week post-vaccination is crucial, particularly for older adults. Further research is warranted to elucidate the underlying mechanisms linking vaccines and GBS.https://doi.org/10.1038/s41598-024-74729-2GlobalGuillain-Barré syndromeVaccineVaccine-associated Guillain-Barré syndromeWorld Health Organization |
| spellingShingle | Yi Deun Jeong Seoyoung Park Sooji Lee Woojin Jang Jaeyu Park Kyeongmin Lee Jinseok Lee Jiseung Kang Raphael Udeh Masoud Rahmati Seung Geun Yeo Lee Smith Hayeon Lee Dong Keon Yon Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 Scientific Reports Global Guillain-Barré syndrome Vaccine Vaccine-associated Guillain-Barré syndrome World Health Organization |
| title | Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 |
| title_full | Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 |
| title_fullStr | Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 |
| title_full_unstemmed | Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 |
| title_short | Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023 |
| title_sort | global burden of vaccine associated guillain barre syndrome over 170 countries from 1967 to 2023 |
| topic | Global Guillain-Barré syndrome Vaccine Vaccine-associated Guillain-Barré syndrome World Health Organization |
| url | https://doi.org/10.1038/s41598-024-74729-2 |
| work_keys_str_mv | AT yideunjeong globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT seoyoungpark globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT soojilee globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT woojinjang globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT jaeyupark globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT kyeongminlee globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT jinseoklee globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT jiseungkang globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT raphaeludeh globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT masoudrahmati globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT seunggeunyeo globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT leesmith globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT hayeonlee globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 AT dongkeonyon globalburdenofvaccineassociatedguillainbarresyndromeover170countriesfrom1967to2023 |